Larvol Delta - Global-Cord-Blood-Corporation-Announced-Cellenkos-Receives-FDA-Clearance-of-IND-Application-for-CK0804-as-Add-on-Therapy-to-Ruxolitinib-for-the-Treatment-of-Myelofibrosis

CK0804 - Cellenkos, Incyte

https://www.prnewswire.com/news-releases/global-cord-blood-corporation-announced-cellenkos-receives-fda-clearance-of-ind-application-for-ck0804-as-add-on-therapy-to-ruxolitinib-for-the-treatment-of-myelofibrosis-301569662.html

Jun 16, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next